SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: billkirn who wrote (4075)4/16/1998 2:45:00 PM
From: Joe E.  Read Replies (1) of 6136
 
Agouron continues to ramp up sales and profits in line with expectations. Their next drug, though, looks to be a couple of years away, assuming AG3340 makes the cut. So there are not any huge surprises just over the horizon, just the usual slogging.

Biotechnology investors love the mystery of the hunt for the silver bullet drug that will cause the stock to triple. Big drug company investors love the steady growth and the broad product lines that give safety and steadily increasing earnings. Agouron is in the misty middle.

I think AGPH is worth 45+ and this is another one of those buying opportunities. Better buying opportunities are likely to arise, but this one looks OK.

Bill - like your site.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News